DiNuzzo Private Wealth’s Neurocrine Biosciences NBIX Stock Holding History

DiNuzzo Private Wealth’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.02K	Hold	12	–	–	﹤0.01%	669
2026 Q1	$1.58K	Hold	12	–	–	﹤0.01%	722
2025 Q4	$1.7K	Hold	12	–	–	﹤0.01%	704
2025 Q3	$1.68K	Hold	12	–	–	﹤0.01%	702
2025 Q2	$1.51K	Buy	12 +4	+50%	+$459	﹤0.01%	714
2025 Q1	$885	Sell	8 -6	-43%	-$760	﹤0.01%	871
2024 Q4	$1.91K	Buy	14 +6	+75%	+$742	﹤0.01%	617
2024 Q3	$922	Sell	8 -1	-11%	-$137	﹤0.01%	885
2024 Q2	$1.24K	Buy	9 +4	+80%	+$549	﹤0.01%	705
2024 Q1	$690	Hold	5	–	–	﹤0.01%	863
2023 Q4	$659	Buy	+5	New	+$576	﹤0.01%	872

Other funds holding NBIX

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

PBBUPS

PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return

Aware Super Sydney, Australia $7.06B AUM

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return

DiNuzzo Private Wealth's NBIX Position: Q2 2026 in Review

DiNuzzo Private Wealth held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 12 shares worth $2.02K. The position accounts for ﹤0.01% of the portfolio, ranked #669.

DiNuzzo Private Wealth first reported a position in NBIX in Q4 2023 and has held it in 11 quarters since. 239 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

DiNuzzo Private Wealth held 12 shares of Neurocrine Biosciences worth $2.02K as of Q2 2026.
DiNuzzo Private Wealth left its Neurocrine Biosciences share count unchanged in Q2 2026.
Neurocrine Biosciences made up ﹤0.01% of DiNuzzo Private Wealth's portfolio in Q2 2026, its #669 holding.
DiNuzzo Private Wealth first reported a position in Neurocrine Biosciences in Q4 2023 and has held it in 11 quarters since.
239 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on DiNuzzo Private Wealth's 13F filing for Q2 2026, filed 10 Jul 2026.